Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Executive Insights – Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Executive Insights | US/EU5 | 2022

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder caused by inflammation and demyelination of the peripheral nerves characterized by weakness associated with loss of reflexes. Multiple approved immunoglobulins (IVIgs, SCIgs), low-cost generic off-label corticosteroids, and PLEX are available for the management of CIDP. However, there are ample opportunities for new players developing novel therapies, particularly targeting refractory patients—a sizeable patient pool—to address the need for effective therapies that are safe and provide long-term relief with chronic use. Given the high unmet need for better treatment alternatives that are effective over the long-term, physicians are likely to adopt these new therapies even if they provide modest benefit over the available treatment options. These brands can command premium pricing if they fulfill the need, particularly if they are effective in the treatment-refractory patient segment.

Questions answered

  • What is the diagnosed prevalence of CIDP, and how are these patients diagnosed and treated in the different markets under study?
  • What are the key unmet needs and areas of opportunity in the management of CIDP?
  • What is the potential impact of pipeline therapies, and how will these therapies affect future market dynamics in CIDP?
  • What are the key drivers and limiters of the CIDP market?
  • What are the challenges associated with the market access and reimbursement of current and new therapies in CIDP?

Product description

Executive Insights provides indication-specific market intelligence withworld-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.


United States, EU5 (France, Germany, Italy, Spain United Kingdom).

Primary research

13 KOL interviews from November 2021 to January 2022.

Key company covered

CSL Behring, Grifols, Octapharma, Takeda, Argenx, Sanofi, Pfizer, Biotest, others.

Key drugs covered

Gamunex, Privigen, Panzyga, Gammaked, Octagam, Kiovig / Gammagard, Flebogamma, Hizentra, HyQvia, efgartigimod, and SAR445088.

launch Related Market Assessment Reports